# Neuralite

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/neuralite

- Industry: Software
- Headquarters: Tel Aviv, Israel
- Website: www.neuralight.ai
- Total disclosed funding: $31M
- Latest round: Series A (Apr 6, 2022)
- Investors on record: 9

## About

Neuralite Ltd is an innovative company specializing in the design and implementation of advanced neurological clinical trials, leveraging cutting-edge technology to enhance research efficacy and patient outcomes.Founded in 2021 and headquartered in Tel Aviv, Israel, Neuralite Ltd focuses on improving the process of neurological clinical trials. The company was co-founded by Micha Breakstone, who has a strong background in technology and innovation. Neuralite has successfully undertaken 2 deals, with its most recent funding round occurring on April 6, 2022. The company raised USD 25.00 mn in a Series A round led by Koch Disruptive Technologies, with participation from Alumni Ventures Group, Breyer Capital, Samsung NEXT Ventures, and VSC Ventures. This funding round represents the total amount raised to date.Neuralite Ltd provides advanced solutions for neurological clinical trials, utilizing innovative technology designed to streamline trial processes and enhance data collection. The company's services are aimed at research institutions and healthcare providers, facilitating the development of new treatments and therapies through improved trial methodologies.Neuralite Ltd operates on a subscription-based model, generating revenue through fees associated with its innovative clinical trial services. Clients engage with the company by selecting tailored service plans that cater to their specific research needs, contributing to a steady stream of recurring revenue.Following its recent funding round on April 6, 2022, where Neuralite Ltd raised USD 25.00 mn, the company intends to utilize this capital to enhance the design of neurological clinical trials. Neuralite plans to expand its services into new markets, targeting regions in North America and Europe by the end of 2023, which will support their goal of improving clinical trial outcomes and efficiency.

## Funding rounds

- Series A, Apr 6, 2022, $25M — Breyer Capital, Alumni Ventures Group, Samsung NEXT Ventures, Koch Disruptive Technologies, VSC Ventures
- Seed, Oct 28, 2021, $5.5M — Tuesday Capital, Operator Partners, MS&AD Ventures, Kli Capital, VSC Ventures

## Investors

- Tuesday Capital (https://capitalatlas.ai/funds/tuesday-capital) — Seed
- Operator Partners — Seed
- MS&AD Ventures (https://capitalatlas.ai/funds/ms-ad-ventures) — Seed
- Kli Capital (https://capitalatlas.ai/funds/kli-capital) — Seed
- VSC Ventures (https://capitalatlas.ai/funds/vsc-ventures) — Seed, Series A
- Breyer Capital (https://capitalatlas.ai/funds/breyer-capital) — Series A
- Alumni Ventures Group (https://capitalatlas.ai/funds/alumni-ventures-group) — Series A
- Samsung NEXT Ventures (https://capitalatlas.ai/funds/samsung-next-ventures) — Series A
- Koch Disruptive Technologies (https://capitalatlas.ai/funds/koch-disruptive-technologies) — Series A